tirzepatide diabetes trial New research from the SURPASS-EARLY found that improved glycemic control, body weight, and waist circumference over 104 weeks compared with intensified conventional care in adults with early type 2 Preliminary results on the Tirzepatide

Semaglutide is a long-acting GLP-1 receptor agonist, which means it works in your body for longer, and youll need to take this medication less often than you would if it was a short-acting GLP-1 such as liraglutide

Unlike small molecules, GLP-1 peptides can trigger immune responses influenced by: manufacturing process impurity patterns formulation differences Even when PK looks comparable, ADA development can alter drug exposure, efficacy, and long-term safetysomething regulators are paying close attention to

GABA helps calm down the nervous system by reducing activity in the brain

In clinical trials, average weight loss was roughly 13% to 17% of starting body weight over ~6468 weeks